MINNEAPOLIS, MN, US, Oct. 12, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company will be releasing the results of a clinical study conducted by Ethos Veterinary Health at the American College of Veterinary Surgeons (“ACVS”) annual conference on the completion of a clinical study, which examined the benefit and tolerability of an intra-articular injection of a collagen-elastin biomaterial (i.e. Spryng™ with OsteoCushion™ Technology) into the stifle joint of dogs with suspected cruciate ligament rupture. Dr. Erik Kleeman, DVM will be presenting the poster at ACVS.
“We were pleased to have the final results of the Spryng clinical study offered in a poster presentation at the ACVS annual conference as this data demonstrates the efficacy of this product as an excellent, non-invasive alternative for patients with cranial cruciate disease,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We continue to strive to provide data demonstrating that Spryng is a viable tool to use in the management of joint related afflictions and thereby enhancing the lives of companion animals and their owners.”
Spryng is an injectable veterinary medical device comprised of millions of micronized extracellular matrix particles, which are derived from natural components, including collagen and elastin. OsteoCushion Technology provides both reinforcing natural joint support to augment and/or reinforce missing and damaged cartilage, as well as delivers natural scaffolding to help address tissue defects. These attributes offer a great solution to manage lameness and joint afflictions, such as osteoarthritis, for companion animals in a simple in-clinic administration.
The dogs enrolled in this study had been diagnosed with a partial or complete cranial cruciate ligament tear (similar to an ACL tear in humans). The primary endpoint of the study was to demonstrate whether there was a significant reduction in pain after Spryng injection, as measured by the modified Glasgow Composite Pain Scale; a significant reduction of pain by 25% or greater would be considered a beneficial response. There were significant improvements in all of the primary and secondary clinical variables throughout the study period (pain, lameness, quality of life scoring). In summary, this study demonstrates that Spryng™ is a reasonable, non-invasive alternative for patients with cranial cruciate disease (“CCD”) when patient and/or owner factors preclude surgical intervention. To view the poster presentation and a video interview of Dr. Kleeman discussing the clinical study presented at the ACVS annual conference please visit the following:
https://www.sprynghealth.com/acvs-2023-poster-presentation?fbclid=IwAR3VuoyNy8wdqFnnArkNsjI-HzTXtXo49jDI3WOn8-835jMBf5spy451O6E
About Ethos Veterinary Health
Ethos Veterinary Health is a unique and impactful science-focused animal health company with an emphasis on collaboration, evidence-based decision making, a commitment to the veterinary ethos, and cultivation of passion for what we do. The Company operates 145 hospitals across the United States, with over 2000 Doctors of Veterinary Medicine, providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members, and innovation. For more information, visit www.ethosvet.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit https://petvivo.com/ or http://sprynghealth.com.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
